CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh

The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/CD3 and CD28 it will have chosen a transcriptional programme it largely keeps for life. That choice is made by whichever cytokines happen to be at the synapse, transduced by a specific STAT and locked in by a master transcription factor. Get the cytokine milieu wrong in a model and you get the wrong disease.

Three signals, and why only the third specifies lineage

Activating a naive CD4⁺ T cell needs peptide–MHC-II through TCR/CD3 and co-stimulation through CD28. Together these drive autocrine IL-2, which signals via STAT5 to power clonal expansion. What they do not do is specify a lineage. Antigen dose and TCR dwell time bias the outcome — brief, low-affinity contacts favour Th2 and Tfh, strong sustained signalling favours Th1 and Th17 — but bias is not instruction. The instructive input is signal 3.

Signal 3 is read by a small set of STATs, one per lineage: STAT4 for Th1, STAT6 for Th2, STAT3 for Th17 and Tfh, STAT5 for iTreg. None is lineage-specific — STAT3 serves a dozen receptors, STAT5 all the γc cytokines — so specificity comes from acting on an enhancer landscape freshly remodelled by TCR signalling. The STAT then installs a master transcription factor, necessary but not sufficient: without the cytokine present through the first cell cycle to close the feedback loop, the phenotype stays partial.

Th1: IL-12, STAT4 and T-bet

Dendritic cells sensing intracellular pathogens produce IL-12, acting through IL-12Rβ2 and STAT4. In parallel, early IFN-γ from NK cells signals via STAT1 to induce T-bet (TBX21). The order is often taught backwards: STAT1 comes first and installs T-bet, and T-bet then upregulates IL-12Rβ2 so the cell can respond to IL-12 at all. A naive cell without T-bet is effectively deaf to IL-12.

The output is macrophage M1 activation and cell-mediated immunity against intracellular bacteria and protozoa. T-bet does double duty: it transactivates Ifng and binds GATA3 to block its access to the Th2 locus, so the factor that builds one programme dismantles its nearest competitor. Because IFN-γ drives its own STAT1 loop, Th1 responses grow progressively harder to redirect — a practical reason to intervene early with anti-IFN-γ.

Th2: IL-4, STAT6 and GATA3

IL-4 signalling through STAT6 induces GATA3, which remodels the Il4/Il5/Il13 locus, autoactivates its own promoter and represses STAT4 to close the Th1 route. The awkward question — where the first IL-4 comes from, when Th2 cells are its main source — is answered by basophils, mast cells, innate lymphoid cells and a trickle from the T cell itself under weak TCR stimulation. That bootstrapping loop is why Th2 polarisation in vitro is far more sensitive to starting cytokine concentration than Th1.

The output is helminth expulsion, eosinophilia, IgE class switching and B-cell help. A point that matters for readouts: IL-13, not IL-4, is the dominant effector in airway hyperresponsiveness and goblet-cell metaplasia, while IL-4 is chiefly the differentiation and isotype-switching signal — so assaying IL-4 alone understates the response. GATA3 is likewise dose-sensitive rather than binary; quantify it rather than scoring presence or absence.

The TGF-β fork: Th17 versus iTreg

TGF-β sits at the most consequential branch point in the pathway, and by itself specifies nothing. With IL-2 and STAT5 it induces FOXP3 and an induced regulatory T cell. Add IL-6 and STAT3 fires instead, RORγt (RORC) is induced, and the same precursor becomes Th17. STAT5 and STAT3 compete for overlapping sites at the Il17 locus, so the IL-2 to IL-6 ratio at priming sets the outcome directly — and since effectors consume the IL-2 Tregs need, the two compartments share one limiting resource.

Th17 cells make IL-17A and IL-22 to defend mucosal barriers; the iTreg arm makes IL-10 and further TGF-β to resolve inflammation. IL-23 does not initiate the Th17 lineage — naive cells lack IL-23R — but it stabilises it and licenses the pathogenic, GM-CSF-producing state seen in autoimmune models. That is why IL-23 blockade controls psoriasis without abolishing protective Th17 immunity, and why an IL-23 readout says more late in a model than at priming.

Tfh, Bcl-6 and the limits of lineage

IL-6 and IL-21 signalling through STAT3 induce Bcl-6, the master repressor defining T-follicular-helper cells. Tfh cells relocate to the follicle, deliver help to B cells and secrete IL-21, and are the requirement for germinal-centre formation and affinity maturation. Tfh and Th17 share both IL-6 and STAT3 upstream; what separates them is Bcl-6, which represses RORγt along with the other master regulators.

Cross-inhibition among T-bet, GATA3, RORγt, FOXP3 and Bcl-6 makes the subsets look discrete, but the boundaries leak. RORγt⁺T-bet⁺ ‘ex-Th17’ cells appear in colitis and EAE and are the pathogenic population in several models; FOXP3⁺ cells can lose FOXP3 under inflammation and acquire effector cytokines. So a single transcription-factor stain, or a single cytokine ELISA, can misclassify a response outright. Measure the regulator and its cytokine together, at more than one time point, and treat co-expression as data rather than as a staining artefact.

Key targets and matching reagents

Studying T-helper differentiation in vivo

Almost every node on this map is a surface receptor or a soluble cytokine, which makes the pathway unusually amenable to functional-grade antibodies. Experiments divide into three groups; the full In Vivo range is low-endotoxin and azide-free.

1. Delivering signal 1 and signal 2

Anti-CD3 (145-2C11) and anti-CD28 are the standard stimulus, plate-bound or soluble in vitro and given systemically in vivo. Adding anti-IL-2 (JES6-1A12) is the cleanest test of whether a phenotype depends on the STAT5 arm, since it withdraws the FOXP3-supporting signal without touching the TCR.

2. Neutralising the polarising cytokines

Anti-IFN-γ (XMG1.2), anti-IL-4 (11B11) and anti-TGF-β (1,2,3) map onto the Th1, Th2 and Th17/iTreg branches, and anti-IL-10 releases the regulatory brake. Combining them is standard: anti-IFN-γ plus anti-IL-4 is the conventional permissive background for Th17 or iTreg induction, because each lineage's effector cytokine suppresses the others.

3. Reading out which programme was chosen

Quantify the master regulators — T-bet, GATA3, RORγt, FOXP3, Bcl-6 — alongside the STATs that induced them (STAT1, STAT4, STAT6, STAT3, STAT5), then confirm at the effector level with ELISAs for IL-12, IL-6, IL-23, IL-13, IL-17A, IL-22 and IL-21.

Featured products for this pathway

Frequently asked questions

For research use only. Not for use in diagnostic or therapeutic procedures.